Document Type

Article

Publication Date

10-1-2025

Comments

This article is the author's final published version in Frontiers in Oncology, Volume 15, 2025, Article number 1600709.

The published version is available at https://doi.org/10.3389/fonc.2025.1600709 Copyright © 2025 Palecki, Tucker, Bernstein, Melby, Zhan and Micaily.

Abstract

Lung cancer (LC) is the leading cause of cancer death in people living with HIV (PLWH) and disproportionately affects this group regardless of CD4 count. At the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Jefferson Health, we treat an underserved PLWH population with LC and aim to study their clinical course, as they are often excluded from LC trials. We retrospectively reviewed 36 PLWH diagnosed with LC at Jefferson Health from 2016 to 2023. We found that 24 patients were male, 20 patients were Black, and that the median age of LC diagnosis is 66 years (range 38-83 years). 27 patients had non-small cell lung cancer (NSCLC) (20 adenocarcinoma, 7 squamous), 3 had small cell lung cancer (SCLC). 24 patients had undetectable viral loads, and 35 patients were on antiviral therapy. Advanced-stage disease was seen in 32 patients, with a 1.3-year OS (95% CI: 0.8-3.8 years). Of 18 patients with molecular testing available, 4 had KRAS mutations, and 1 had targetable EGFR mutations. Of 16 tested for PD-L1, 8 patients had 1-49% expression, and 1 patient had >50%. Our cohort showed more advanced disease at presentation, younger age at diagnosis, and poor OS despite most patients having undetectable HIV viral loads on antiviral therapy, suggesting a link between well-controlled HIV and aggressive LC that warrants further study.Copyright © 2025 Palecki, Tucker, Bernstein, Melby, Zhan and Micaily.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Additional Files
Supplemental_Figure_1.jpg (32 kB)
Supplemental_Table_1.jpg (142 kB)

PubMed ID

41103944

Language

English

Download

Share

COinS